Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional

An Oral, Direct Factor Xa Inhibitor, BAY59-7939, for Prophylaxis Against Venous Thromboembolism After Total Knee Replacement: a Dose-Ranging Study

ClinicalTrials.gov ID: NCT00402467

Public ClinicalTrials.gov record NCT00402467. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 23, 2026, 6:20 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Study identification

NCT ID
NCT00402467
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Bayer
Industry
Enrollment
613 participants

Conditions and interventions

Interventions

  • Rivaroxaban, (BAY59-7939) Drug
  • Enoxaparine Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jan 31, 2004
Primary completion
Oct 31, 2004
Completion
Oct 31, 2004
Last update posted
Dec 22, 2014

2004

United States locations

U.S. sites
15
U.S. states
8
U.S. cities
14
Facility City State ZIP Site status
Not listed Birmingham Alabama 35205
Not listed Phoenix Arizona 85023
Not listed Tucson Arizona 85712
Not listed La Mesa California 91942-3019
Not listed Torrance California 90502-2004
Not listed Aurora Colorado 80011-6798
Not listed Aurora Colorado 80012
Not listed Jacksonville Florida 32216
Not listed Palm Beach Gardens Florida 33410
Not listed Sarasota Florida 34239
Not listed St. Petersburg Florida 33703
Not listed Decatur Georgia 30033
Not listed Cincinnati Ohio 45219
Not listed Dallas Texas 75231
Not listed Lubbock Texas 79410

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 21 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00402467, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Dec 22, 2014 · Synced Jul 23, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00402467 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →